Proteus Digital Health: sourced choices

6 product and go-to-market choices, oldest first. Back to the case study

2017-11Product · Device chain Medication ingestion information passed through a sensor, patch and phone application. PR2
2017-11Product · Detection limitations The approved label warned that ingestion detection could be delayed or missed. PR2
2017-11Product · Clinical evidence Improvement in patient adherence had not been established in the label. PR2
2018-10-11Go_To_Market · Development funding Otsuka described $88 million in equity and other payments. PR6
2018-10-11Go_To_Market · Expansion plan The collaboration planned broader products and next-generation development. PR6
2020-08-25Go_To_Market · Asset purchase Otsuka completed a purchase of selected assets and liabilities. PR5